Topic: Psychopharmacology

	Personalized Program The Personalized Program enables you to compile an individual program with events and contributions of your interest. Therefore, it can be used very well to plan your actual congress visit at an early point of time. Please log in to use the Personalized Program.	» Login » Identification » Help

	Sunday, 28. June 2009	next day »

No.	S-06 - Symposium
Time:	08.00-09.30
Room:	Room 251
Topic:	Psychopharmacology
Track:	1 Basic
Session title:	The endocannabinoid system in psychiatric disorders: From basic neuroscience to clinical practice
	F. Markus Leweke, Germany	Chair
	Daniele Piomelli, Italy	Co-Chair

001	Breakdown of cell assembly synchronization by CB1 receptor activation
	György Buzsaki, Hungary	Speaker
002	Endocannabinoids in anxiety and depression
	Daniele Piomelli, Italy	Speaker
003	eCB, processing reward-related stimuli and substance use disorders
	Rajita Sinha, USA	Speaker
004	Translational studies on eCBs in schizophrenia: Bench to bedside
	F. Markus Leweke, Germany	Speaker

No.	S-08 - Symposium
Time:	11.00-12.30
Room:	Salle Maillot
Topic:	Psychopharmacology
Track:	1 Basic
Session title:	Non-classical mechanisms of action of antidepressants
	Rainer Rupprecht, Germany	Chair
	Mark Rasenick, USA	Co-Chair

001	Role of lipid rafts for antidepressant induced G-protein signalling
	Mark Rasenick, USA	Speaker
002	Modulation of ligand-gated ion channels by antidepressants
	Rainer Rupprecht, Germany	Speaker
003	Role of P-glycoprotein for HPA axis activity and antidepressant treatment
	Carmine Pariante, United Kingdom	Speaker
004	5-HT6 receptor stimulation regulates excitatory and inhibitory neurotransmission and induces neuronal plasticity: Potential mechanisms for antidepressant drug action and neuroprotection
	Lee Schechter, USA	Speaker

No.	FC-06 - Free Communications
Time:	12.30-14.00
Room:	Room 242B
Topic:	Psychopharmacology
Session title:	Psychopharmacology I
	F. Markus Leweke, Germany	Chair
	David Janowsky, USA	Co-Chair

001	Effects of chronic lithium administration on renal function in the intellectually disabled
	David Janowsky, USA	Speaker
002	Baseline lipid levels and treatment response to paroxetine and tianeptine in depressed women
	Marina Sagud, Croatia	Speaker
003	Impact of escitalopram compared to amitriptyline on polysomnographically recorded sleep, daytime sleepiness and performance: A randomized, double-blind, placebo-controlled study in healthy male subjects
	Ulrich Voderholzer, Germany	Speaker
004	Enhancing effects of chronic lithium on memory in the rat
	Dimitrios Kontis, Greece	Speaker
005	Immediate versus gradual suspension of previous treatments during switch to aripiprazole: Results of a randomized, open label study
	Alberto Chiesa, Italy	Speaker
006	Reduced blood BDNF mRNA levels in depressed patients are normalized by antidepressant treatment
	Anna Maria Cattaneo, Italy	Speaker

No.	P-10 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Psychopharmacology
Session title:	Psychopharmacology/Antidepressants
	Thomas Raedler, Canada	Chair

001	Corticotropin - releasing factor receptor 1 antagonist attenuates neurochemical responses against swim stress in the rodent brain
	Ayako Ohashi, Japan	Presenter
002	Treatments patterns, resource use and related healthcare costs in depressed patients with co-morbid anxiety in a large US claims database
	Florent Guelfucci, France	Presenter
003	Induction of violence by psychotropic drugs: Signal detection
	David Menkes, New Zealand	Presenter
004	Violence as a side - effect of antidepressants: Provocation by alcohol
	David Menkes, New Zealand	Presenter
005	Antidepressants for prevention of interferon-alpha-induced depression: A meta-analysis
	Bruno Fábregas, Brazil	Presenter
006	Antidepressants post-receptor mechanism of action involves beta-arrestins and extracellular signal-regulated kinases
	Moran Golan, Israel	Presenter
007	A case of neuroleptic malignant syndrome induced by atypical antipsychotics
	Feryal Cam Celikel, Turkey	Presenter
008	Venlafaxine-associated manic episode in a young depressive patient
	Feryal Cam Celikel, Turkey	Presenter
009	Antidepressants inhibit microglial activation: The possibility of a novel therapeutic effect
	Hideki Horikawa, Japan	Presenter
010	Effect of antidepressant therapy on brain neurotrophic factors, brain ERK system and cognitive performance of rats exposed to chronic mild stress
	Abraham Weizman, Israel	Presenter
011	The 5-HT2B receptor is necessary for the behavioral and neurogenic effects induced by chronic SSRI treatment
	Silvina Laura Diaz, France	Presenter
012	Peripheral biomarkers are modulated by early-life stress and antidepressant treatment in a gene-environment interaction model of depressive disorder in rats
	Lucia Carboni, Italy	Presenter
013	The TREK-1 potassium channel as a new antidepressant target
	Marc Borsotto, France	Presenter
014	The efficacy of Desvenlafaxine 50 mg/d for improving anxiety symptoms in patients with major depressive disorder: A pooled analysis
	Karen Tourian, France	Presenter
015	Antidepressant psychotropic/ psychological effects in healthy subjects
	Alessandro Serretti, Italy	Presenter
016	Effect of the p38 MAP kinase inhibitor SB-239063 on behaviour and peripheral biomarkers in the Lipopolysaccharide (LPS) induced sickness model in rats
	Silvia Bison, Italy	Presenter
017	The involvement of GABAA receptor in the molecular mechanism of combined antidepressant and antipsychotic treatment
	Lena Danovich, Israel	Presenter
018	A slow vs standard up-titration with Paroxetine in the treatment of panic disorder
	Bernardo Dell’Osso, Italy	Presenter
019	Effects of commercially available products of St John’s Worth in Serbia on forced swimming and tail suspension tests in mice
	Vladimir Janjic, Serbia and Montenegro	Presenter
020	Escitalopram as monotherapy in major Depressive Disorder with insomnia
	Vladimir Janjic, Serbia and Montenegro	Presenter

No.	W-04 - Workshop
Time:	16.00-17.30
Room:	Room 242B
Topic:	Psychopharmacology
Session title:	Clozapine and lithium - gold-standard or outdated treatment?
	Thomas Raedler, Canada	Chair

001	Current use of lithium
	Michael Bauer, Germany	Speaker
002	Current use of clozapine
	Herbert Meltzer, USA	Speaker


« previous day	Monday, 29. June 2009	next day »

No.	S-29 - Symposium
Time:	08.00-09.30
Room:	Room 252B
Topic:	Psychopharmacology
Track:	2 Clinical
Session title:	Antipsychotic treatment of aggression in the intellectually disabled - a growing controversy
	David Janowsky, USA	Chair
	Sherva Elizabeth Cooray, United Kingdom	Co-Chair

001	Antipsychotic withdrawal induced activation of aggression in the intellectually disabled
	David Janowsky, USA	Speaker
002	Evidence for the effectiveness of antipsychotic medications to manage problem behaviors in adults with intellectual disability
	Shoumitro Deb, United Kingdom	Speaker
003	Antipsychotic agents in the treatment of autism
	David Posey, USA	Speaker
004	The argument against antipsychotic agents in the intellectually disabled
	Sherva Elizabeth Cooray, United Kingdom	Speaker

No.	D-03 - Debate
Time:	11.00-12.30
Room:	Room 351
Topic:	Psychopharmacology
Session title:	Should we keep using benzodiazepine?
	Jean-Pierre Lepine, France	Chair

	Christer Allgulander, Sweden	Proponent
	Mathias Berger, Germany	Opponent

No.	P-20 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Psychopharmacology
Session title:	Psychopharmacology I
	Robertas Bunevicius, Lithuania	Chair

001	Mirtazapine and sertraline in pregnancy and lactation
	Bettina Schletterer, Austria	Presenter
002	Assessment of 3-methoxy-4-hydroxyphenylglycol (MHPG), cortisol and cognitive performance in patients with anxiety, neuroticism and allostatic load, under treatment with alprazolam
	Carlos Alberto Soria, Argentina	Presenter
003	Cycloserine and fluvoxamine combined pharmacotherapy of refractory obsessive-compulsive disorder (OCD) among adolescents
	Maruke Yeghiyan, Armenia	Presenter
004	Decrease in benzodiazepine binding is a possible sign of fear and anxiety
	Ksenia Chekina, Russia	Presenter
005	New drugs elaboration for neurodegenerative disorders treatment based on KYNA - receptor binding mechanism
	Gennady Zakharov, Russia	Presenter
006	Influence of Solcoseryl on immune system and inflammatory-destructive processes in central nervous system in patients with cerebral arteriosclerosis
	Palamarchuk Iryna, Ukraine	Presenter
007	Effect of Methylphenidate - a point of view from a cell
	Jasmin Bartl, Germany	Presenter
008	Comparison of milnacipran, duloxetine and pregabalin in the formalin pain test and in a model of conditioned stress-induced ultrasonic vocalizations in rat
	Ronan Depoortere, France	Presenter
009	Immunological efficacy of preparation cytoflavin in therapy of borderline mental disorders
	Valentina Nikitina, Russia	Presenter
010	The use of atypical antipsychotic in Saudi Arabia
	Khalaf Aljumaah, Saudi Arabia	Presenter
011	Sexual dysfunction during risperidone and haloperidol treatment in schizophrenia
	Dragan Vukic, Serbia and Montenegro	Presenter
012	Clozapine withdrawal catatonia and neuroleptic malignant syndrome: A case report and literature review
	Magdalena Spariosu, USA	Presenter
013	Anticonvulsant activity and neurotoxicity of 3-(z)-[1-(aniline)ethylidene]-4,5-dihydrofuran-2(3h) - one derivatives in mice
	Christian Rodríguez, Venezuela	Presenter
014	Monotherapy versus antipsychotic combination in maintenance treatment of schizophrenia: Expirience from two wards in specialized psychiatric hospital "Gornja Toponica"
	Milan Stanojkovic, Serbia and Montenegro	Presenter
015	Agonism and inverse agonism at the benzodiazepine site of GABAA receptors: The influence on spontaneous locomotor activity and spatial memory
	Janko Samardzic, Serbia and Montenegro	Presenter
016	Drop - outs of patients in psychotherapy v/s patients in psychotherapy and pharmacotherapy
	Panagiotis Papadopoulos, Greece	Presenter
017	Task related adjustment of motorcortical excitability measured by transcranial magnetic stimulation (TMS) in normal adults pre and post methylphenidate (MPH) administration
	Johannes Buchmann, Germany	Presenter
018	Therapeutic Effects of Alpha-Lipoic Acid in Treatment of Diabetic Neuropathy
	Sibin Vladejic, Serbia and Montenegro	Presenter
019	Psychoneuroimmunomodulating effect of atypical neuroleptics
	Tamara Vetlugina, Russia	Presenter
020	Effects of Piracetam on brain BDNF, NMDA- and nicotinic receptor content in mice
	Julia Firstova, Russia	Presenter


« previous day	Tuesday, 30. June 2009	next day »

No.	S-45 - Symposium
Time:	08.00-09.30
Room:	Room 352AB
Topic:	Psychopharmacology
Track:	3 Interface
Session title:	Are biological measures useful in predicting antipsychotic treatment response in schizophrenia?
	Monte Buchsbaum, USA	Chair
	Herbert Meltzer, USA	Co-Chair

001	Prediction of antipsychotic response with diffusion tensor imaging
	M. Mehmet Haznedar, USA	Speaker
002	Pharmacogenetic prediction of antipsychotic response
	Maria Arranz, United Kingdom	Speaker
003	Predicting best treatment response in schizophrenia with striatal function
	Erin Hazlett, USA	Speaker
004	Loudness dependence of auditory evoked potentials as predictor of therapeutical response to psychotropic medication
	Georg Juckel, Germany	Speaker

No.	D-05 - Debate
Time:	11.00-12.30
Room:	Room 351
Topic:	Psychopharmacology
Session title:	Are psychotropic drugs overprescribed to pregnant women ?
	Birte Glenthoj, Denmark	Chair

	Angelika Wieck, United Kingdom	Proponent
	Pierre Thomas, France	Opponent

No.	FC-19 - Free Communications
Time:	12.30-14.00
Room:	Room 242A
Topic:	Psychopharmacology
Session title:	Psychopharmacology II
	Christer Allgulander, Sweden	Chair
	Herbert Meltzer, USA	Co-Chair

001	Characteristic of clozapine responders & non-responders in a naturalistic tertiary setting in India
	Amresh Shrivastava, Canada	Speaker
002	Effects of Olanzapine and Risperidone on glucose metabolism and Insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: A randomized five month study
	Robert C. Smith, USA	Speaker
003	Antipsychotic polypharmacy and use of sedatives and hypnotics in outpatients at Birch Hill Hospital - incidence and adherence to guidelines
	Nadezda Ranceva, United Kingdom	Speaker
004	Patterns of Risperidone long acting prescription: A utilization study in Saudi Arabia
	Khalaf Aljumaah, Saudi Arabia	Speaker
005	Antioxidant neuroprotection by neuroleptics revisited
	Parvana Hajieva, Germany	Speaker
006	Fitness to drive under escitalopram or mirtazapine
	Gerd Laux, Germany	Speaker

No.	P-28 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Psychopharmacology
Session title:	Psychopharmacology/ Antipsychotics
	James L. Kennedy, Canada	Chair

001	Trend in antipsychotic polypharmacy: A review of emergency prescriptions in a psychiatric hospital in Romania
	Madalina Ionelia Vrabie, Romania	Presenter
002	High dose of escitalopram in the treatment of obsessive compulsive disorder in a teaching hospital in Malaysia
	Amer Siddiq Amer Nordin, Malaysia	Presenter
003	A method to reduce polypharmacy and maximize effectiveness in chronically mentally Ill patients
	Andre Tapp, USA	Presenter
004	Antidepressant effect of antipsychotics in Schizophrenia: Comparison of typical and atypical antipsychotic drugs
	Antonio Sá, Brazil	Presenter
005	Obsessive-compulsive symptoms and disorder in patients with schizophrenia treated with clozapine or haloperidol
	Antonio Sá, Brazil	Presenter
006	Translation from the dopamine-glutamate interaction to antipsychotic pharmacotherapy: Role of Homer
	Carmine Tomasetti, Italy	Presenter
007	Acute efficacy of Olanzapine long-acting injection, oral Olanzapine, and haloperidol in patients with schizophrenia: A cross-study comparison
	Chris Bushe, USA	Presenter
008	Weight gain and changes in metabolic parameters during treatment with antipsychotics and Metformin : A systematic review of clinical studies
	Chris Bushe, USA	Presenter
009	Striatal and Extrastriatal D2/3-receptor binding properties of Quetiapine
	Hildegard Janouschek, Germany	Presenter
010	Glutamate and adenosine receptors mediate transcriptional activity induced by dopamine D2 antagonists in the striatum
	Jerome Maheux, Canada	Presenter
011	Efficacy and tolerability among patients with recent onset schizophrenia treated with long - acting injectable risperidone - PROPEL study
	Jonathan Rabinowitz, Israel	Presenter
012	Premorbid functioning and treatment response among patients with recent onset schizophrenia: Prospective study with risperidone long-acting injectable - PROPEL study
	Jonathan Rabinowitz, Israel	Presenter
013	Psychosis and Hiperprolactinemia in male patient: Contributions to pathophysiology and treatment
	Jose Lisandro Pabon Davila, Venezuela	Presenter
014	Repeated occurrence of clozapine-induced myocarditis in a patient with schizoaffective disorder and comorbid Parkinson´s disease
	Ladislav Hosak, Czech Republic	Presenter
015	Asenapine: An overview of phase I pharmacokinetic studies
	Pierre Peeters, Netherlands	Presenter
016	Amelioration of MK-801-induced cognitive impairment by lurasidone in mouse contextual fear conditioning test
	Satoko Baba, Japan	Presenter
017	Quetiapine Alleviates the Cuprizone-induced Demyelination and promotes the Remyelination Following Withdrawal of Cuprizone
	Xin-Min Li, Canada	Presenter
018	Risperidone long-acting injectable and Olanzapine pamoate: Review of short- and long-term safety data
	Guadalupe Martinez, Spain	Presenter
019	Descriptive analyses of the aripiprazole arm in the Risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE)
	Guadalupe Martinez, Spain	Presenter
020	Functional improvement in Schizophrenia and schizoaffective disorder: Results from the Risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE)
	Guadalupe Martinez, Spain	Presenter

No.	P-29 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Psychopharmacology
Session title:	Psychopharmacology/ Antidepressants
	Pierandrea Muglia, United Kingdom	Chair

002	Frequency of treatment-emergent sexual dysfunction in outpatients with major depressive disorder treated with either duloxetine or a selective serotonin reuptake inhibitor antidepressant: 8-week observational data
	Hector Duenas, Mexico	Presenter
003	Anxiolytic - and antidepressant-like effects in multiple preclinical assays shown by Lu AA21004, a novel drug
	Bjarke Ebert, Denmark	Presenter
004	Lu AA21004, a novel drug for the treatment of mood disorders: In vitro profile
	Bjarke Ebert, Denmark	Presenter
005	Lu AA21004, a novel potential treatment for mood disorders: In vivo effects
	Bjarke Ebert, Denmark	Presenter
007	Imipramine reverses oxidative damage in rat hippocampus in the absence and presence of chronic inhaled ozone: Support for a role of oxidative stress in depression
	Christiaan Brink, South Africa	Presenter
008	Duloxetine versus escitalopram in the treatment of major depressive disorder and generalized anxiety disorder dual diagnosis
	Daniel Vasile, Romania	Presenter
009	Milnacipran efficacy in major depressive disorder and alcohol dependence dual diagnosis
	Daniel Vasile, Romania	Presenter
010	Tianeptine efficacy in the treatment of multiple sclerosis associated anxiety disorder
	Daniel Vasile, Romania	Presenter
011	Comparison of Sertralines efficacy and tolerance with those of Clomipramine during the treatment of patients with obssessive compulsive disorder
	Elga Spaho, Albania	Presenter
012	A unifying theory of antidepressant action
	Francis Lavergne, France	Presenter
013	Cyclooxygenase (COX)-2 inhibition in depression: Evidence from animal studies
	Inge Sillaber, Germany	Presenter
014	Sexually dimorphic effects of antidepressant imipramine on glucocorticoid receptor hormone binding properties and association with heat shock proteins in the rat liver and kidney
	Ivana Elakovic, Serbia and Montenegro	Presenter
015	Preperential prevention of apoptosis by citalopram in mouse cortical cell cultures
	Jai-Sung Noh, Korea, Republic of	Presenter
017	Effect of monoaminergic antidepressant drugs on the hippocampal neurogenesis in a model of depression
	Parichehr Hassanzadeh, Iran	Presenter
019	Paroxetine specificity profile in major depression
	Sara Gibiino, Italy	Presenter
020	The role of fluoxetine in treatment of obsessive-compulsive disorder and co-substance abuse-a case report
	Mira Krivokuca, Serbia and Montenegro	Presenter
021	The most severe somatic disorders treated with excitalopram - more than just survival
	Sanja Kaludjerovic, Serbia and Montenegro	Presenter
022	The most severe somatic disorders treated with excitalopram
	Sanja Kaludjerovic, Serbia and Montenegro	Presenter
001	Tandospirone augmentation therapy is useful in depressed patients with inadequate response to SSRIs or SNRIs (Subsequent report)
	Akitsugu Sumiyoshi, Japan	Presenter

No.	S-56 - Symposium
Time:	16.00-17.30
Room:	Room 352AB
Topic:	Psychopharmacology
Track:	3 Interface
Session title:	Recent developments in affective disorders during pregnancy and lactation
	Angelika Wieck, United Kingdom	Chair
	Carmine Pariante, United Kingdom	Co-Chair

001	Recent developments in antenatal depression
	Carmine Pariante, United Kingdom	Speaker
002	New data on the reproductive safety of antidepressant drugs
	Margareta Reis, Sweden	Speaker
003	New insights into bipolar disorder in childbearing women
	Ian Jones, United Kingdom	Speaker
004	The safety of mood stabilizing medication in pregnancy and lactation
	Salvatore Gentile, Italy	Speaker


« previous day	Wednesday, 1. July 2009	next day »

No.	FC-25 - Free Communications
Time:	08.00-09.30
Room:	Room 242B
Topic:	Psychopharmacology
Session title:	Psychopharmacology III
	Stuart Montgomery, United Kingdom	Chair
	Monte Buchsbaum, USA	Co-Chair
	Daniel J. Mueller, Canada	Co-Chair

001	Impact of depression, anxiety comorbidity and antidepressant treatment on heart rate variability: A meta-analysis
	Daniel Quintana, Australia	Speaker
002	Social isolation alters the behavior effect of carbamazepine
	Noppamars Wongwitdecha, Thailand	Speaker
003	Effects of antipsychotics and vitamin C on the formation of reactive oxygen species
	Philip Heiser, Germany	Speaker
004	Chronic SSRI treatment in female rats: Dissociation of antidepressant action from hippocampal BDNF expression
	Anita C. Hansson, Germany	Speaker
006	The efficacy of eicosapentaenoic acid for major depression: Results of the OMEGA-3D trial
	Francois Lesperance, Canada	Speaker

No.	S-69 - Symposium
Time:	11.00-12.30
Room:	Room 252B
Topic:	Psychopharmacology
Track:	1 Basic
Session title:	Promises and pitfalls of genetic research in drug treatment of depression and schizophrenia
	Daniel J. Mueller, Canada	Chair
	James L. Kennedy, Canada	Co-Chair

001	Results from a whole genome association study in depression: Will putative etiologic genes predict antidepressant response?
	Pierandrea Muglia, United Kingdom	Speaker
002	Impact of MAOA-, COMT- and serotonergic system gene variants in antidepressant drug treatment
	Katharina Domschke, Germany	Speaker
003	Pharmacogenetics of antidepressants in mood disorders, what can be improved? A proposal for methodological guidelines
	Alessandro Serretti, Italy	Speaker
004	Pharmacogenetics of antipsychotics using an animal model
	Dan Rujescu, Germany	Speaker

No.	FC-28 - Free Communications
Time:	12.30-14.00
Room:	Room 242B
Topic:	Psychopharmacology
Session title:	Psychopharmacology IV
	Larry Siever, USA	Chair
	Alessandro Serretti, Italy	Co-Chair

001	The effect of Ketamine on sensorimotor gating - comparison of human and animal data
	Tomas Palenicek, Czech Republic	Speaker
002	Treatment resistant catatonia responding to zolpidem: Case reports and literature review
	Cristinel Coconcea, USA	Speaker
003	Rapid metabolism of antipsychotics and akathisia in schizophrenic Court-Order detention patients: A selection bias
	Carel de Blécourt, Netherlands	Speaker
004	Acute Stress Responsiveness of BDNF in the rat prefrontal cortex is modulated by antidepressants
	Therese M. Jay, France	Speaker
005	Dexamphetamine effects on prepulse inhibition of the startle reflex in healthy volunteers
	Mathew Martin-Iverson, Australia	Speaker
006	Efficacy of amantadine in the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study
	Sofia Pappa, United Kingdom	Speaker

No.	P-38 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Psychopharmacology
Session title:	Psychopharmacology II
	Brian E. Leonard, Ireland	Chair

001	Comparison of Olanzapine long-acting injection switching methods: An 8-month analysis of patients with schizophrenia at risk of relapse
	Elena Perrin, USA	Presenter
002	Long-term open-label safety of olanzapine long-acting injection: 190-week interim results
	Elena Perrin, USA	Presenter
003	Different art therapies applied with the antipsychotics
	Elizabeth Peli-Hasz, Hungary	Presenter
004	Eating disorders: Bibliotherapeutics to increase the pharmacotherapeutic compliance
	Elizabeth Peli-Hasz, Hungary	Presenter
005	Effect of alcoholic extract of hypericum perforatum on fear behavior in adult male rats
	Gholamhassan Vaezi, Iran	Presenter
006	Effect of inhalation alcoholic extract of Peganum harmala, on induction of anxiety like behavior in elevated plus-maze
	Gholamhassan Vaezi, Iran	Presenter
007	What pharmacological agents are most efficacious for the treatment of cognitive and behavioural problems following traumatic brain injury?
	Jane Mathias, Australia	Presenter
008	A randomized, placebo-controlled, double-blind, crossover study to investigate the residual effects of ramelteon (8 mg) and zopiclone (7.5 mg) on actual driving, memory, psychomotor performance and body balance in healthy volunteers
	Joris Verster, Netherlands	Presenter
009	Methylphenidate significantly improves declarative memory functioning in adult patients with Attention-Deficit Hyperactivity Disorder (ADHD)
	Joris Verster, Netherlands	Presenter
010	Can MDR 1 Polymorphism predict the side effect of oros-methylphenid in children and adolescents with Attention Deficit/ Hyperactivity Disorder?
	Ki-Hwan Yook, Korea, Republic of	Presenter
011	Prevalence of Metabolic Syndrome in chronic female patients
	Liliana Rendon, Paraguay	Presenter
012	Clinical interest of measuring out serical valproic acid rate in psychiatry
	Jean-Michel Pinoit, France	Presenter
013	Depressive syndromes and suicides of subjects treated with varenicline: Psychiatric and neurobiolological aspects
	Romain Padovani, France	Presenter
014	Atypical antipsychotics and social functioning in schizophrenic patients
	Marijo Vrdoljak, Croatia	Presenter
015	Maintaining of long-term effect of wellness program in psychiatric patients
	Sladjana Strkalj Ivezic, Croatia	Presenter
016	Reward sensitivity and response to the augmentation with topiramate in treatment-resistant anxiety
	Sorina Elena Nastase, Romania	Presenter
017	Topiramate in psychiatry as illustrated by an inpatient data base
	Sorina Elena Nastase, Romania	Presenter
018	The beneficial effect of Milnacipran on Fibromyalgia is not related to its antidepressant effects: A European, Multicenter, Controlled Trial
	Yves Mainguy, France	Presenter
019	The effect of Milnacipran on pain modulatory systems in Fibromyalgia: An FMRI analysis
	Richard Gracely, USA	Presenter
020	Control of Tourette’s syndrome with Paliperidone and Topiramate: A case report
	Ioanna Fotara, Greece	Presenter

No.	P-39 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Psychopharmacology
Session title:	Pschopharmacology/ Antipsychotics II
	Georg Juckel, Germany	Chair

001	Gabapentin is an important adjuvant in the treatment of resistant schizophrenia
	Caroline Demily, France	Presenter
002	Next-generation GRII antagonist prevents and reverses antipsychotic-induced weight gain
	Robert Roe, USA	Presenter
003	Mifepristone reduces weight gain associated with Risperidone use
	Robert Roe, USA	Presenter
004	Use of nicotine as augmentation agent in schizophrenia treatment
	Christos Tsopelas, Greece	Presenter
005	Atypical antipsychotics combination at medical discharge from psychiatry hospitalization unit
	Cristina Domenech Abella, Spain	Presenter
006	Treatment of severe hospitalized bipolar affective and schyzoaffective disorders in naturalistic conditions: Gender differencies
	Cristina Domenech Abella, Spain	Presenter
007	Prepulse inhibition of the startle response in amisulpride - treated patients: Comparison with typical antipsychotics
	Gabriel Rubio, Spain	Presenter
008	Expirience with zuclopenthixol on female forensic ward in specializad psychiatric hospital "gornja toponica"
	Jelena Mladenovic, Serbia and Montenegro	Presenter
009	Influence of clopixol monotherapy on improvement of quality of life in inpatient conditions on female forensic ward in specialized Psychiatric Hospital "gornja toponica"
	Jelena Mladenovic, Serbia and Montenegro	Presenter
010	Psychological stress and body temperature: Effects of Alprazolam and Flupentixol
	Juliane Hellhammer, Germany	Presenter
011	Haloperidol and atypical antipsychotics in the long-term treatment of psychotic disorders: Preliminary data from a naturalistic study
	Massimo Carlo Mauri, Italy	Presenter
012	Quetiapine and hypothyroidism: A literature review
	Vassilis Kontaxakis, Greece	Presenter
013	Spontaneous resolution of quetiapine induced hypothyroidism without quetiapine discontinuation
	Vassilis Kontaxakis, Greece	Presenter
014	Impact of haloperidol and Quetiapine on the expression of genes encoding antioxidant enzymes in human Neuroblastoma SH-SY5Y cells
	Philip Heiser, Germany	Presenter
015	Effect of perospirone on sLORETA images of P300 and social cognition in schizophrenia
	Tomiki Sumiyoshi, Japan	Presenter
016	Cognitive remediation therapy in schizophrenia: Experience of a 12-month follow up group
	Veronique Lambolez, France	Presenter
017	Use of aripiprazole and clozapine in the treatment of resistant schizophrenia: Two case reports
	Veronique Lambolez, France	Presenter
018	The A-effect of aripiprazole
	Xiaolei Yu Baran, USA	Presenter
019	Flexible doses of paliperidone ER in non-acute patients with schizophrenia switched due to lack of tolerability with their previous oral antipsychotic
	Dagmar Hoeben, Belgium	Presenter
020	A flexible-dose study of paliperidone ER in non-acute patients with schizophrenia previously unsuccessfully treated with oral risperidone
	Dagmar Hoeben, Belgium	Presenter
021	Safety, tolerability and treatment response of flexible doses of Paliperidone ER in acutely exacerbated patients with schizophrenia
	Dagmar Hoeben, Belgium	Presenter

No.	D-08 - Debate
Time:	16.00-17.30
Room:	Room 351
Topic:	Psychopharmacology
Session title:	Are there alternatives to placebo controlled studies for efficacy?
	Stuart Montgomery, United Kingdom	Chair

	Olivier Blin, France	Proponent
	Corrado Barbui, Italy	Opponent


« previous day	Thursday, 2. July 2009

No.	FC-32 - Free Communications
Time:	08.00-09.30
Room:	Room 242A
Topic:	Psychopharmacology
Session title:	Psychopharmacology V
	Joseph Zohar, Israel	Chair
	Liliana Rendon, Paraguay	Co-Chair

001	Pisa Syndrome induced by atypical antipsychotics
	Susana Mendes, Portugal	Speaker
002	Randomized placebo controlled trials of n-acetyl cysteine as adjunct therapy for schizophrenia and bipolar disorder
	Olivia Dean, Australia	Speaker
003	Prevalence of lower-than-expected plasma levels in medicated patients presenting for acute inpatient treatment
	Christian Geretsegger, Austria	Speaker
004	The anxiolytic etifoxine reduces the physical signs and anxiogenic effects of ethanol withdrawal in mice
	Marc Verleye, France	Speaker
005	Effects of sertindole on MK-801 induced impairment of memory in radial arm maze test
	Ipek Komsuoglu Celikyurt, Turkey	Speaker
006	Early perturbation in feeding behavior and energy homeostasis in olanzapine-treated rats
	Renaud de Beaurepaire, France	Speaker

No.	S-83 - Symposium
Time:	11.00-12.30
Room:	Room 252B
Topic:	Psychopharmacology
Track:	3 Interface
Session title:	Newer antipsychotic drugs: From neuroplasticity to neurotherapy
	Frank Tarazi, USA	Chair
	Marco Riva, Italy	Co-Chair

001	Neuroplasticity and signaling in the action of atypical antipsychotic drugs: Implications for functional recovery
	Marco Riva, Italy	Speaker
002	Receptor neuroplasticity of newer antipsychotic drugs
	Frank Tarazi, USA	Speaker
003	Serotonergic properties of antipsychotic drugs: Relevance to neuroplasticity
	Mohammed Shahid, United Kingdom	Speaker
004	Neuroplasticity as a target for innovative treatments. Effect of Clozapine in two animal models of schizophrenia.
	William T. O'Connor, Ireland	Speaker

No.	P-48 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Psychopharmacology
Session title:	Psychopharmacology/ Antipsychotics III
	Noppamars Wongwitdecha, Thailand	Chair

001	Reasons for olanzapine discontinuation in Japanese patients with schizophrenia.－ Comparison with the results of CATIE －
	Akihisa Akahane, Japan	Presenter
002	Evaluating clozapine dose - response relationship using EEG monitoring
	Amresh Shrivastava, Canada	Presenter
003	Does Neuroendocrine offer an outcome predictive indicator: Experience of Serum Prolactin in 5 year outcome in first episode drug naive patients
	Amresh Shrivastava, Canada	Presenter
004	Does Serum Prolactin elevation & Prolactin related side effects of atypical antipsychotics represent a Prolactin-Dopamine subgroup in schizophrenia
	Amresh Shrivastava, Canada	Presenter
006	Tolerability, safety and treatment response of flexible doses of paliperidone ER in recently diagnosed patients with schizophrenia
	Andreas Schreiner, Germany	Presenter
007	Long-term remission in schizophrenia and schizoaffective disorder: Results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE)
	Andreas Schreiner, Germany	Presenter
008	Atypical neuroleptic risperidone modulates astroglial functions
	Carmem Gottfried, Brazil	Presenter
009	Differential effects of olanzapine, risperidone and haloperidol on serum brain - derived neurotrophic factor levels and psychopathological variables in chronic schizophrenic patients
	Emmanouil Rizos, Greece	Presenter
010	Skill proceduralization in schizophrenia - the differential effect of typical and atypical neuroleptics
	Emmanuelle Pourcher, Canada	Presenter
011	5-HT2A receptor occupancy in first episode schizophrenia patients treated with quetiapine
	Hans Rasmussen, Denmark	Presenter
012	The metabolism of chlorpromazine by human cytochrome P450 isoenzymes - a comparison with other phenothiazines
	Jacek Wójcikowski, Poland	Presenter
013	Asenapine improves a subchronic phencyclidine-induced deficit in object recognition memory in the rat
	Jo Neill, United Kingdom	Presenter
014	The effects and characteristics of high-dose Quetiapine (equal/higher than 800mg/day) use
	Jeung-Gee Kim, Korea, Republic of	Presenter
015	Interaction of Aripiprazole with Citalopram and MDMA: Potential role of SEROTONIN 5-HT2B receptor antagonism
	Marie-Bernadette Assie, France	Presenter
017	Effects of olanzapine on visual recognition memory in mice
	Oguz Mutlu, Turkey	Presenter
018	The use of atypical antipsychotics in patients with substance-related disorders and posttraumatic stress disorder and their self-perception of quality of life
	Slaven Zudenigo, Croatia	Presenter
019	CIPS: A naturalistic study of Consta in Polynesian subjects
	Sylvester Wayne Miles, New Zealand	Presenter
020	Risk factors of aripiprazole treatment discontinuation in japanese schizophrenia patients
	Yoshiteru Takekita, Japan	Presenter

No.	P-49 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Psychopharmacology
Session title:	Psychopharmacology III
	Alessandro Serretti, Italy	Chair

001	Prevalence of drug induce psychosis among amphetamine and methamphetamine dependence patients
	Ahmad Hatim Sulaiman, Malaysia	Presenter
002	Safety and efficacy of aripiprazole in the treatment of amphetamine and methamphetamine induce psychosis: A preliminary results
	Ahmad Hatim Sulaiman, Malaysia	Presenter
003	Aripiprazole’s intrinsic activity is not enhanced on striatal membranes of rat chronically pre-treated with haloperidol
	Beryl Koener, Belgium	Presenter
004	Comparative evaluation of the predictors that diferentiate Valproate’s effect in the long-term treatment of Bipolar Disorders (BD)
	Fatime Elezi, Albania	Presenter
005	Efficacy comparison of Lamotrigine versus Lithium Carbonate in Bipolar Disorder II (BP II) patients treated for the first time with mood stabilizer
	Anila Kazaferi, Albania	Presenter
006	Evaluation of anxiolytic properties of the diethyl ether extract of Gentiana kochiana
	Gordana Tovilovic, Serbia and Montenegro	Presenter
007	Long-term efficacy and saftey of galantamine in outpatients with mild cognitive disorder
	Julio Zarra, Argentina	Presenter
008	Mild cognitive disorder and depression: Treatment with association between Galantamine and Escitalopram
	Julio Zarra, Argentina	Presenter
009	Therapy of addition for Alzheimer's disease: Combination with Galatamine and Memantine
	Julio Zarra, Argentina	Presenter
010	Limited anti-apoptotic activity of valproic acid on leukemic cell line
	Krzysztof Pietruczuk, Poland	Presenter
011	New perspectives: Atypical anxiolytics block the development of ethanol -and benzodiazepine withdrawal-induced anxiety in experiment
	Larisa Kolik, Russia	Presenter
012	Anxiety disorders in primary care: Effects of anxiolytic treatments on cognitive functions, a French naturalistic study
	Fadwa Cazala, France	Presenter
013	Pentoxifylline Ameliorates Methamphetamine - induced cognitive deficits
	Ming-Huan Chan, Taiwan	Presenter
014	Yokukansan supresses methamphetamine-induced hyperlocomotion in mice
	Naoki Uchida, Japan	Presenter
015	5 - HT2C receptor activation inhibits stress - induced increase in 5 - HT transmission: Relevance of receptor desensitization to the anxiolytic effect of chronic parocentine in mice
	Laurence Lanfumey, France	Presenter
019	Management alopecia induced by mood stabilizers
	Susana Mendes, Portugal	Presenter
020	Translocation of sigma 1 receptors from the cytoplasm to vicinity of the plasma membrane in response to Afobazol treatment
	Tatyana Antipova, Russia	Presenter

No.	W-13 - Workshop
Time:	14.00-15.30
Room:	Room 251
Topic:	Psychopharmacology
Session title:	Drugs, hormones and psychoneuroimmunoendocrinology
	Raquel Teresa Zamora-Cabral, Uruguay	Chair

001	Stress, the immune system and depression
	Brian E. Leonard, Ireland	Speaker
002	Psychopharmacology on the feminine vital cycle
	Liliana Rendon, Paraguay	Speaker
003	Psychiatric effects of hormones
	Andrea Lopez Mato, Argentina	Speaker
004	Hormonal Effects of Psychiatric Drugs
	Raquel Teresa Zamora-Cabral, Uruguay	Speaker

« Back

Topic: Psychopharmacology

Sunday, 28. June 2009

Monday, 29. June 2009

Tuesday, 30. June 2009

Wednesday, 1. July 2009

Thursday, 2. July 2009